BITT-CD4F10 / Boston Immune Tech - LARVOL DELTA

BITT Provides Update on DOMab Platform and CD40 Program (Businesswire) - "Boston Immune Technologies and Therapeutics, Inc...announced today updates on the company’s DOMab™ platform. Two DOMab CD40 antagonists (BITT-CD4D11 and BITT-CD4F10) have completed discovery and optimization and a final candidate is being selected for IND-enabling steps. BITT-CD4D11 and BITT-CD4F10 are being developed for indications in autoimmunity and inflammation including Crohn’s disease, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome....'We will be presenting preclinical data from both the CD40 and TNFR2 programs at conferences in the first half of 2023.'"

Pipeline update • Preclinical • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis